Patents by Inventor Sven-Niklas Anders Axelsson

Sven-Niklas Anders Axelsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC AGENTS AND USES THEREOF
    Publication number: 20220125961
    Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.
    Type: Application
    Filed: January 7, 2022
    Publication date: April 28, 2022
    Inventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
  • THERAPEUTIC AGENTS AND USES THEREOF
    Publication number: 20200138986
    Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.
    Type: Application
    Filed: November 11, 2019
    Publication date: May 7, 2020
    Inventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
  • Therapeutic Agents and Uses Thereof
    Publication number: 20160317683
    Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.
    Type: Application
    Filed: April 21, 2016
    Publication date: November 3, 2016
    Inventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
  • Therapeutic agents and uses thereof
    Patent number: 9345782
    Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: May 24, 2016
    Assignee: FREDAX AB
    Inventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
  • Therapeutic Agents and Uses Thereof
    Publication number: 20140286862
    Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.
    Type: Application
    Filed: October 26, 2012
    Publication date: September 25, 2014
    Inventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson